+

WO2000053191A3 - Modulation of skeletal muscle precursor cell activation - Google Patents

Modulation of skeletal muscle precursor cell activation Download PDF

Info

Publication number
WO2000053191A3
WO2000053191A3 PCT/CA2000/000255 CA0000255W WO0053191A3 WO 2000053191 A3 WO2000053191 A3 WO 2000053191A3 CA 0000255 W CA0000255 W CA 0000255W WO 0053191 A3 WO0053191 A3 WO 0053191A3
Authority
WO
WIPO (PCT)
Prior art keywords
skeletal muscle
muscle precursor
modulation
cell activation
precursor cell
Prior art date
Application number
PCT/CA2000/000255
Other languages
French (fr)
Other versions
WO2000053191A2 (en
Inventor
Judy E Anderson
Original Assignee
Univ Manitoba
Judy E Anderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba, Judy E Anderson filed Critical Univ Manitoba
Priority to AU31395/00A priority Critical patent/AU3139500A/en
Priority to CA002371927A priority patent/CA2371927A1/en
Priority to US09/936,609 priority patent/US6967102B1/en
Publication of WO2000053191A2 publication Critical patent/WO2000053191A2/en
Publication of WO2000053191A3 publication Critical patent/WO2000053191A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to methods, pharmaceutical compositions and kits for modulating skeletal muscle precursor cell activation. Modulation is effected through the use of nitric oxide (NO), donors of NO, inhibitors of NO activity (NO inhibitor) or regulators of NO production, either locally or systemically. The invention further teaches the use of NO, an NO donor, an NO inhibitor or a regulator of NO production to modulate the effects of steroid hormone on skeletal muscle. The invention further provides a method for identifying a compound which effects a change in activation state of muscle precursor cells. A number of advantages is evident. By allowing skeletal muscle precursor cells to be manipulated directly, the invention enables specific treatments to regenerate and repair muscle, especially for the muscular dystrophies.
PCT/CA2000/000255 1999-03-11 2000-03-10 Modulation of skeletal muscle precursor cell activation WO2000053191A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU31395/00A AU3139500A (en) 1999-03-11 2000-03-10 Modulation of skeletal muscle precursor cell activation
CA002371927A CA2371927A1 (en) 1999-03-11 2000-03-10 Nitric oxide manipulation of muscle satellite cell activation
US09/936,609 US6967102B1 (en) 1999-03-11 2000-03-10 Nitric oxide manipulation of muscle satellite cell activation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12389599P 1999-03-11 1999-03-11
US60/123,895 1999-03-11

Publications (2)

Publication Number Publication Date
WO2000053191A2 WO2000053191A2 (en) 2000-09-14
WO2000053191A3 true WO2000053191A3 (en) 2001-09-13

Family

ID=22411541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000255 WO2000053191A2 (en) 1999-03-11 2000-03-10 Modulation of skeletal muscle precursor cell activation

Country Status (3)

Country Link
AU (1) AU3139500A (en)
CA (1) CA2371927A1 (en)
WO (1) WO2000053191A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794647A1 (en) * 1999-06-11 2000-12-15 Centre Nat Rech Scient PHARMACEUTICAL COMPOSITIONS COMPRISING NO OR AT LEAST A COMPOUND CAPABLE OF RELEASING OR INDUCING THE FORMATION OF NO IN CELLS
AU2003226603A1 (en) 2002-04-19 2003-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
WO2007088050A2 (en) * 2006-02-03 2007-08-09 San Raffaele Centro Fond Method of treatment for muscular dystrophy
WO2007088123A2 (en) * 2006-02-03 2007-08-09 Nicox S.A. Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
RU2391968C1 (en) * 2008-12-29 2010-06-20 Учреждение Российской академии наук Государственный научный центр Российской Федерации Институт медико-биологических проблем Российской академии наук Method of preventing cytosceletal proteins destruction in sceletal muscles within eccentric load
WO2010108843A1 (en) 2009-03-27 2010-09-30 Nicox S.A. Use of nitrooxyderivative of paracetamol for the treatment of muscular dystrophies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
WO1997033173A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
JPH10120654A (en) * 1996-10-17 1998-05-12 Ono Pharmaceut Co Ltd Nitrogen monoxide synthase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
WO1997033173A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
JPH10120654A (en) * 1996-10-17 1998-05-12 Ono Pharmaceut Co Ltd Nitrogen monoxide synthase inhibitor

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
AZZENA G B ET AL: "NITRIC OXIDE REGENERATES THE NORMAL COLONIC PERISTALTIC ACTIVITY IN MDX DYSTROPHIC MOUSE", NEUROSCIENCE LETTERS,LIMERICK,IE, vol. 261, no. 1/02, 1999, pages 9 - 12, XP000879028, ISSN: 0304-3940 *
AZZENA GIAN BATTISTA ET AL: "Nitric oxide regenerates the normal colonic peristaltic activity in mdx dystrophic mouse.", NEUROSCIENCE LETTERS, vol. 261, no. 1-2, 12 February 1999 (1999-02-12), pages 9 - 12, XP000961771, ISSN: 0304-3940 *
BREDT DAVID S: "NO skeletal muscle derived relaxing factor in Duchenne muscular dystrophy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 25, December 1998 (1998-12-01), Dec., 1998, pages 14592 - 14593, XP000960480, ISSN: 0027-8424 *
CHAO DANIEL S ET AL: "Selective loss of sarcolemmal nitric oxide synthase in becker muscular dystrophy.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 2, 1996, pages 609 - 618, XP000961763, ISSN: 0022-1007 *
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C PHARMACOLOGY TOXICOLOGY &, vol. 118, no. 3, November 1997 (1997-11-01), Nov., 1997, pages 375 - 379, ISSN: 0742-8413 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, BAEK MI-YEONG ET AL: "Changes in the cellular cGMp levels and guanylate cyclase activities during chick myoblast fusion.", XP002154299, Database accession no. PREV199396097003 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1997 (1997-11-01), LAMOSOVA D ET AL: "Influence of melatonin on chick skeletal muscle cell growth.", XP002154300, Database accession no. PREV199800098087 *
DATABASE WPI Section Ch Week 199831, Derwent World Patents Index; Class B03, AN 1998-350696, XP002154301 *
EL-DADA, MANAR D. ET AL: "Involvement of nitric oxide in nicotinic receptor-mediated myopathy", J. PHARMACOL. EXP. THER. (1997), 281(3), 1463-1470, XP000972194 *
HAYCOCK J W ET AL: "OXIDATIVE DAMAGE TO MUSCLE PROTEIN IN DUCHENNE MUSCULAR DYSTROPHY", NEUROREPORT,GB,RAPID COMMUNICATIONS OF OXFORD, OXFORD, vol. 8, no. 1, 1996, pages 357 - 361, XP000879014, ISSN: 0959-4965 *
KALIMAN, PERLA ET AL: "Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-.kappa.B and inducible nitric-oxide synthase define a common myogenic signaling pathway", J. BIOL. CHEM. (1999), 274(25), 17437-17444, XP000960874 *
KOREAN JOURNAL OF ZOOLOGY, vol. 36, no. 3, 1993, pages 433 - 438, ISSN: 0440-2510 *
LEE KUN HO ET AL: "Nitric oxide as a messenger molecular for myoblast fusion.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 20, 1994, pages 14371 - 14374, XP002154298, ISSN: 0021-9258 *
SARKAR RAJABRATA ET AL: "Nitric oxide inhibition of endothelial cell mitogenesis and proliferation.", SURGERY (ST LOUIS), vol. 118, no. 2, 1995, pages 274 - 279, XP000961764, ISSN: 0039-6060 *
SOHN YOON K ET AL: "Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases.", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 162, no. 2, 15 January 1999 (1999-01-15), pages 133 - 151, XP000961766, ISSN: 0022-510X *
ULIBARRI J A ET AL: "Nitric oxide stimulates myoblast proliferation in vitro.", MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, vol. 29, no. 5 SUPPL., 1997, 44th Annual Meeting of the American College of Sports Medicine;Denver, Colorado, USA; May 28-31, 1997, pages S228, XP000961780, ISSN: 0195-9131 *
YAN ZHONG-QUN ET AL: "Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells.", CIRCULATION RESEARCH, vol. 82, no. 1, pages 21 - 29, XP000961767, ISSN: 0009-7330 *

Also Published As

Publication number Publication date
AU3139500A (en) 2000-09-28
WO2000053191A2 (en) 2000-09-14
CA2371927A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
AU5401900A (en) Coating method and coating mixture
HUP0001454A2 (en) Compositions and methods for treating plants with exogenous chemicals
ATE311406T1 (en) INHIBITOR AND STIMULATOR OF PROLIFERATION OF HAEMATOPOIETIC STEM CELLS AND THEIR APPLICATIONS
WO2004038000A3 (en) Methods of using substituted tetracycline compounds to modulate rna
GB2421837A (en) Generating sets of tailored laser pulses
IE39120B1 (en) Dentifrices
WO2000046383A3 (en) Method of modulating metabolite biosynthesis in recombinant cells
MY121627A (en) Progesterone for treating or reducing ischemia
MY127021A (en) System and method for maintenance charging of battery cells
RU94046041A (en) NOVEL METHOD FOR PRODUCTION OF 7β-SUBSTITUTED 4-AZA-5α-ANDROSTANE-3-ONES
WO2000053191A3 (en) Modulation of skeletal muscle precursor cell activation
WO2002026727A3 (en) Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai
NO994309L (en) Methods for suppressing tumor growth with combinations of isoprenoids and statins
CA2015838A1 (en) Method of topically treating acne vulgaris
CA2242394A1 (en) Process for reduction of total acid number in crude oil
AU2003247812A1 (en) Tool apparatus, system and method of use
IL163650A0 (en) Topical dapsone for the treatment of acne
Fontecave et al. Reduction of the Fe (III)-tyrosyl radical center of Escherichia coli ribonucleotide reductase by dithiothreitol.
AU2668800A (en) Mixture of plant-treatment agents and waxes, method for producing same and the use thereof
DE69431162D1 (en) Fenbendazolformulierungen
EP0344572A3 (en) Composition of angiotensin-converting-enzyme inhibitor with calcium chanell modulators and uses thereof as pharmaceuticals
NZ330300A (en) Treating metal with a polyelectrolyte prior to or simultaneously with formation of a synthetic zeolite used to coat the metal
DE59307136D1 (en) Method of avoiding glue when annealing steel strip
EP0361434A3 (en) Display emulating system
WO2002041832A8 (en) Compositions having comfrey and methods for reducing retinoid-induced skin irritation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371927

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09936609

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载